- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02333565
Combination of Everolimus and Octreotide LAR in Aggressive Recurrent Meningiomas (CEVOREM)
Combination of Everolimus and Octreotide LAR in Aggressive Recurrent Meningiomas.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Contact
- Name: Urielle DESALBRES, Director
- Phone Number: 04.91.38.27.47
- Email: drci@ap-hm.fr
Study Locations
-
-
-
Marseille, France, 13354
- ASSISTANCE PUBLIQUE HOPITAUX MARSEILLE
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Male and Female patients ≥ 18 years old with no maximum limited of age
- Histologically proven meningioma grade II and III; grade I meningioma may also be included, if progression is documented (see criteria 3), particularly in case of skull base location
- Progression is defined on 2 different MRI as an increase of meningioma's surface ≥ 5% by 3 months period (i.e. an increase of 5% over 3 months, 10% over 6 months, 15% over 9 months…) or as the apparition of a new unequivocal neurological symptom related to the meningioma. We considered as a new unequivocal neurological symptom a new occurring neurological symptom as, for instance, hemiparesia, oculomotor nerve palsy, visual loss, facial nerve palsy, facial neuralgia, directly related to meningioma and suggesting meningioma growth with increase of meningioma compression on neurological structures despite no increasing size on MRIs.
- Patients must have failed surgery, and not amenable to a new curative intended surgery
- Patients must have failed radiotherapy and/or radiosurgery
- Prior chemotherapy is allowed, if progression under the cytotoxic agent is clearly documented. An interval of 4 weeks after the last administration of the cytotoxic agent is warranted. Number of prior chemotherapies is not limited.
- Patients who have given their written consent
- Patients affiliated to a social insurance regime
- Adequate bone marrow function as shown by: Absolute Neutrophil Count ≥ 1.5 x 109/L,
- Platelets ≥ 100 x 109/L, Hb >9 g/dL
- Adequate liver function as shown by; serum bilirubin ≤ 1.5 x Upper Limit of Normal; International Normalized Ratio < 1.3; alanine aminotransferase and aspartate aminotransferase ≤ 2.5 x Upper Limit of Normal - Adequate renal function: serum creatinine ≤ 1.5 x Upper Limit of Normal - Fasting serum cholesterol ≤ 300 mg/dL OR ≤ 7.75 mmol/L and fasting triglycerides ≤ 2.5 x Upper Limit of Normal. NOTE: In case one or both of these thresholds are exceeded, the patient can only be included after dyslipidemia treatment initiation.
Exclusion Criteria:
- Patients with symptomatic lithiasis
- Contra indication to octreotide and everolimus
- Women of child-bearing age who are using no effective means of contraception
- Pregnant or breast-feeding women or adults of reproductive potential who are not using effective birth control methods. If barrier contraceptives are being used, these must be continued throughout the trial by both sexes
- Patients receiving other investigational agents or who received an investigative drug or therapy within the last 30 days.
- Known intolerance or hypersensitivity to octreotide, everolimus or other rapamycin (sirolimus, temsirolimus)
- Uncontrolled diabetes mellitus defined by HbA1c>8.5%
- Patients who have any severe and/or uncontrolled medical condition:
unstable angina pectoris, symptomatic congestive heart failure, myocardial infarction ≤ 6 months prior to inclusion, serious uncontrolled cardiac arrhythmia, active or uncontrolled severe infection, cirrhosis, chronic active hepatitis or chronic persistent hepatitis, severely impaired lung function (spirometry and Diffusing Capacity of the lung for carbon monoxide 50% or less of normal and O2 saturation 88% or less at rest on room air), active, bleeding diathesis
- Patients receiving chronic treatment with immunosuppressive agent
- Patients with a known history of HIV seropositivity
- Patients who have a history of another primary malignancy ≤ 3 years, with the exceptions of non-melanoma skin cancer, and carcinoma in situ of uterine cervix.
- Females patients who are pregnant or lactating, or are of childbearing potential and not practicing a medically acceptable method of birth control.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Combinaison everolimus and octreotide
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
The Progression Free Survival rate
Time Frame: 36 months
|
Measured by the number of individuals without progression disease at 6 months, according to Response Assessment in Neuro-Oncology criteria's.
|
36 months
|
Collaborators and Investigators
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimated)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Pathologic Processes
- Nervous System Diseases
- Neoplasms by Histologic Type
- Neoplasms
- Neoplasms by Site
- Disease Attributes
- Neoplasms, Nerve Tissue
- Central Nervous System Neoplasms
- Nervous System Neoplasms
- Neoplasms, Vascular Tissue
- Meningeal Neoplasms
- Recurrence
- Meningioma
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Enzyme Inhibitors
- Antineoplastic Agents
- Immunosuppressive Agents
- Immunologic Factors
- Gastrointestinal Agents
- Antineoplastic Agents, Hormonal
- Protein Kinase Inhibitors
- MTOR Inhibitors
- Octreotide
- Everolimus
Other Study ID Numbers
- 2014-09
- 2014-003694-42 (EudraCT Number)
- RCAPHM14_0080 (Other Identifier: APHM)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Recurrent Meningiomas
-
Kasr El Aini HospitalUnknownNeurocognitive Outcome Assesment in Patients With Perioptic Meningiomas
-
Dana-Farber Cancer InstituteBristol-Myers SquibbRecruitingMeningiomasUnited States
-
Kasr El Aini HospitalUnknownMeningiomas of the Middle Cranial FossaEgypt
-
Tata Memorial HospitalTerry Fox FoundationUnknownCraniopharyngioma | Meningiomas | Ependymomas | Low Grade GliomasIndia
-
City of Hope Medical CenterNational Cancer Institute (NCI)RecruitingRecurrent Glioblastoma | Recurrent Malignant Glioma | Recurrent WHO Grade III Glioma | Recurrent WHO Grade II Glioma | Recurrent Gliosarcoma | Recurrent Anaplastic Astrocytoma | Recurrent Anaplastic Oligoastrocytoma | Recurrent Anaplastic OligodendrogliomaUnited States
-
City of Hope Medical CenterNational Cancer Institute (NCI)Active, not recruitingRecurrent Glioblastoma | Recurrent Malignant Glioma | Recurrent WHO Grade III Glioma | Recurrent Gliosarcoma | Recurrent Anaplastic Astrocytoma | Recurrent Anaplastic Oligoastrocytoma | Recurrent Anaplastic OligodendrogliomaUnited States
-
National Cancer Institute (NCI)CompletedRecurrent Childhood Medulloblastoma | Recurrent Childhood Ependymoma | Recurrent Childhood Anaplastic Astrocytoma | Recurrent Childhood Brain Stem Glioma | Recurrent Childhood Giant Cell Glioblastoma | Recurrent Childhood Glioblastoma | Recurrent Childhood Gliosarcoma | Recurrent Childhood OligodendrogliomaUnited States
-
University of OklahomaGlaxoSmithKlineTerminatedRecurrent Glioblastoma | Recurrent Glioma | Recurrent Astrocytoma | Recurrent OligodendrogliomaUnited States
-
Nanjing UniversityCompletedUnexplained Recurrent Miscarriage and Recurrent Implantation FailureChina
Clinical Trials on Octreotide
-
AdventHealthTerminatedAdenomaUnited States
-
Aspireo Pharmaceuticals LimitedCompleted
-
Mayo ClinicCompletedCirrhosis | Portal Hypertension | Esophageal Varices
-
Chengfeng WangUnknown
-
Novartis PharmaceuticalsCompletedChemotherapy-induced DiarrheaBrazil
-
Qilu Pharmaceutical Co., Ltd.CompletedHealthy VolunteersChina
-
Peking UniversityUnknownEsophageal Neuroendocrine Carcinoma | Gastro-entero-pancreatic CarcinomaChina
-
Qilu Hospital of Shandong UniversityNot yet recruitingNeuroendocrine TumorsChina
-
Azidus BrasilSuspended
-
Cliniques universitaires Saint-Luc- Université...TerminatedNeuroendocrine Tumors | Carcinoid Syndrome